pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Colitis

May 31, 2023

Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

May 17, 2023

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

Mar 28, 2023

Direct Biologics Announces First Patient Dosed with ExoFlo™ in a Phase 1 Clinical Trial for Medically Refractory Ulcerative Colitis

Mar 22, 2023

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease

Jan 19, 2023

Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s and Colitis Congress

Jan 9, 2023

Inotrem Receives Funding From the Crohn’s and Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)

Dec 5, 2022

Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis

Apr 14, 2022

Inotrem and the Crohn’s and Colitis Foundation Sign a RandD Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD)

Apr 13, 2022

Adiso Therapeutics Announces Completion of First Cohort Enrollment in a Phase 1b Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Mar 10, 2022

Morningside Ventures Launches Adiso Therapeutics to Advance Novel Therapies for Inflammatory Diseases

Feb 18, 2022

Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)

Feb 10, 2022

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

Nov 18, 2021

Second Genome Presents Preclinical Data at Crohn's and Colitis Foundation's IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

Jul 21, 2021

Vedanta Biosciences Completes $68 Million Series D Financing

Jul 21, 2021

PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

Jul 13, 2021

Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress

Jul 9, 2021

Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults

Jul 9, 2021

Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)

Jun 30, 2021

PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease

Jun 29, 2021

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

Mar 3, 2021

Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023

Jan 21, 2021

Biomica Announces Participation at the Crohn's and Colitis Congress January 21-24, 2021 (Virtual Conference) USA - English USA - English

Dec 15, 2020

Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

Dec 2, 2020

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis

Jun 9, 2020

Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis

Aug 20, 2019

Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate Ulcerative Colitis

Aug 13, 2019

Landos Biopharma Completes $60 Million Series B Financing

Jul 9, 2019

Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis

Dec 14, 2018

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval for ECMH™ for Treatment of Ulcerative Colitis

Nov 29, 2018

Generex Biotechnology Expands Medical Device and Wound Care Portfolio with Acquisition of Regentys Corporation

Oct 23, 2018

Ixaka Expands Management Team with Multiple Appointments

Jul 10, 2018

Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease

Jul 10, 2018

Vedanta Biosciences Receives Award from the Crohn’s and Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease

Feb 19, 2018

sterna biologicals Reports Phase 2a Study Data Demonstrating Efficacy of Its GATA-3 Specific DNAzyme Formulation SB012 in Patients with Ulcerative Colitis

Feb 14, 2018

Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment

Jan 29, 2018

CutisPharma Announces FDA Approval Of FIRVANQ™ For Treatment Of Clostridium Difficile Associated Diarrhea (CDAD) And Staphylococcus Aureus Colitis

Jan 29, 2018

First Wave Bio Inc. to Begin Clinical Trials of Novel Small-Molecule Therapy for Ulcerative Colitis

Dec 19, 2017

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

Aug 2, 2017

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement

Apr 28, 2017

enGene's mucosal gene delivery platform is successful in targeting PD-L1 expression in the gut, demonstrating effective treatment of colitis and GvHD in preclinical models

Aug 22, 2016

Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis

May 6, 2016

Qu Biologics Awarded Genome BC Funding to Study QBECO Site Specific Immunomodulator (SSI) for Ulcerative Colitis

Mar 18, 2016

Lycera Announces Presentations of Positive Preclinical Results for Lead Candidate LYC-30937 and for Selective Rho kinase Inhibitor Program at the 11th Congress of the European Crohn's and Colitis Organization (ECCO)

Dec 14, 2015

Rebiotix and McMaster Children's Hospital Announce First Patient treated in Largest Randomized Clinical Trial of Fecal Microbial Transplant (FMT) for Pediatric Ulcerative Colitis

Aug 31, 2015

Qu Biologics Opens Additional Ulcerative Colitis Clinical Trial Sites in Edmonton and Hamilton

Jul 28, 2015

Qu Biologics Begins Phase 2 Clinical Trial in Ulcerative Colitis

Jun 5, 2013

Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis